Yes, but it's diminished from what it was.
The long patent protection makes it difficult for the generics to make drugs. At one time we had a program where they could pay a fee to the person who developed the drug, to the company—
On September 26th, 2016. See this statement in context.
September 26th, 2016 / 11:10 a.m.
Saint John Chapter, Council of Canadians
Yes, but it's diminished from what it was.
The long patent protection makes it difficult for the generics to make drugs. At one time we had a program where they could pay a fee to the person who developed the drug, to the company—
See context to find out what was said next.